Since these genetic mutations have been emerged as predictive biomarkers for patients who might fail to EGFR-targeted therapy (79), these preliminary findings indicate that GM may represent a promising therapeutic agent for metastatic colorectal cancer. This evidence concerns the gene EGFR and metastatic colorectal cancer.